Literature DB >> 20660041

Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.

Alessandra Gambineri1, Federica Tomassoni, Daniela Ibarra Gasparini, Antonio Di Rocco, Vilma Mantovani, Uberto Pagotto, Paola Altieri, Stefania Sanna, Anna Maria Fulghesu, Renato Pasquali.   

Abstract

CONTEXT: The determinants of the variability in the clinical response to metformin in women with the polycystic ovary syndrome (PCOS) are enigmatic. Organic cation transporter 1 (OCT1) plays a trigger role in the hepatic uptake of metformin. In cellular studies, it was recently shown that seven polymorphisms of OCT1 exhibit reduced transport of metformin. It is noteworthy that four of the seven variants, R61C (C>T), G401S (G>A), G465R (G>A), and 420del, are present in individuals of European descent.
OBJECTIVE: The aim was testing the hypothesis that polymorphisms in OCT1 may contribute to the variability in the response to metformin in PCOS. DESIGN AND
SETTING: We conducted a prospective study at an academic hospital. PATIENTS: We studied 150 Italian PCOS patients aged 18-45 yr.
INTERVENTIONS: We administered two oral doses of metformin per day for 6 months. MAIN OUTCOME MEASURES: We measured the genotype distribution of R61C, G401S, G465R, and 420del and the influence of genotypes on response to metformin.
RESULTS: Eighty-four PCOS women had the reference allele at all four positions and were classified as "References," whereas 66 PCOS women carried at least one copy of the four polymorphisms (52 carried one polymorphism, 13 carried two polymorphisms, and one carried three polymorphisms) and were classified as "Variants." Only the References reduced their total cholesterol [-14 mg/dl (-22 to -5); P = 0.002] and triglycerides [-17 mg/dl (-29 to -5); P = 0.008]. Insulin(AUC) decreased in References and in Variants carrying one polymorphism, but it did not change in Variants carrying two or more polymorphisms.
CONCLUSIONS: Genetic variation in OCT1 may be associated with heterogeneity in the metabolic response to metformin in women with PCOS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660041     DOI: 10.1210/jc.2010-0145

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 2.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

Review 3.  Metformin pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Srijib Goswami; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

4.  PharmGKB summary: very important pharmacogene information for SLC22A1.

Authors:  Srijib Goswami; Li Gong; Kathleen Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

5.  Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Authors:  Dmitri Madera; Lynn Vitale-Cross; Daniel Martin; Abraham Schneider; Alfredo A Molinolo; Nitin Gangane; Thomas E Carey; Jonathan B McHugh; Christine M Komarck; Heather M Walline; William N William; Raja R Seethala; Robert L Ferris; J Silvio Gutkind
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-13

6.  Association between copy-number variation on metabolic phenotypes and HDL-C levels in patients with polycystic ovary syndrome.

Authors:  Birgit Knebel; Stefan Lehr; Onno E Janssen; Susanne Hahn; Sylvia Jacob; Ulrike Nitzgen; Dirk Müller-Wieland; Jorg Kotzka
Journal:  Mol Biol Rep       Date:  2016-11-22       Impact factor: 2.316

Review 7.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 8.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

9.  Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.

Authors:  Lev M Berstein; Aglaya G Iyevleva; Dmitry Vasilyev; Tatyana E Poroshina; Evgeny N Imyanitov
Journal:  Cell Cycle       Date:  2013-10-21       Impact factor: 4.534

Review 10.  An update on the pharmacogenomics of metformin: progress, problems and potential.

Authors:  Jennifer N Todd; Jose C Florez
Journal:  Pharmacogenomics       Date:  2014-03       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.